MARKET

SNTI

SNTI

Senti Bioscience
NASDAQ
1.170
-0.050
-4.10%
Pre Market: 1.170 0 0.00% 07:48 12/19 EST
OPEN
1.210
PREV CLOSE
1.220
HIGH
1.240
LOW
1.150
VOLUME
109
TURNOVER
0
52 WEEK HIGH
5.44
52 WEEK LOW
1.150
MARKET CAP
30.76M
P/E (TTM)
-0.4184
1D
5D
1M
3M
1Y
5Y
1D
Senti Biosciences Grants Stock Options to New Employee
Reuters · 16h ago
Senti Biosciences Announces New Employment Inducement Grants
Barchart · 22h ago
Promising Potential of SENTI-202 in Treating Acute Myeloid Leukemia: A Buy Recommendation Despite Financial Risks
TipRanks · 4d ago
Weekly Report: what happened at SNTI last week (1208-1212)?
Weekly Report · 4d ago
Promising Phase 1 Results and Favorable Safety Profile Drive Buy Rating for Senti Biosciences’ SENTI-202 in AML Treatment
TipRanks · 12/10 11:25
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers
NASDAQ · 12/10 04:35
Senti Biosciences Is Maintained at Buy by Chardan Capital
Dow Jones · 12/09 20:17
Senti Biosciences Price Target Raised to $13.00/Share From $12.00 by Chardan Capital
Dow Jones · 12/09 20:17
More
About SNTI
Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Webull offers Senti Biosciences Inc stock information, including NASDAQ: SNTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNTI stock methods without spending real money on the virtual paper trading platform.